Scalp-Injected RNA Hair Loss Drug Completes Phase 1b Dosing in Australia
OliX announced on August 4 that it has completed patient dosing in the Australian Phase 1b clinical trial for OLX104C (compound name: OLX72021), an...
Search results for "dosing"
MediPost Begins Pivotal U.S. Phase 3 Trial for Regenerative Knee Therapy Cartistem
South Korean biotechnology company MediPost has entered full-scale Phase 3 clinical testing in the United States for its landmark knee osteoarthritis...
When Supplements Turn Toxic: The Hidden Risks of Over-Dosing on Calcium and Vitamin D
While nutrients found in natural foods rarely cause significant side effects even when consumed in large amounts,...
Don't Take All Your Supplements at Once: A Morning-to-Night Guide to Optimal Timing
Many people take whatever supplements they missed earlier in the day right before bed or wash them down with morning...
Olix Obesity Candidate Reduces Monkeys’ Visceral Fat by 29.2%, Outperforming Global Rival
Olix announced on July 30 that its obesity drug candidate, "OLX501A," significantly outperformed a global rival...
HLB Innovation Expands Phase 1 CAR-T Trial Following Clean Early Safety Data
HLB Innovation announced on July 23 that its U.S. subsidiary, Verismo Therapeutics, has expanded the Phase 1 clinical...
Novo Nordisk Secures EU Green Light for Oral Wegovy, Outpacing Eli Lilly in the Pill Market
The glucagon-like peptide-1 (GLP-1) obesity treatment market, long dominated by subcutaneous injections, is rapidly...
Pack More Than a Passport: The Essential Guide to Travel Vaccines and Malaria Prevention
If you have already packed your bags for peak vacation season, it is still too early to completely relax.
Slowing the Inevitable: How Early Antibody Therapy Is Transforming Alzheimer’s Care
“Lately, I keep forgetting appointments.” “They keep repeating what they just said.”When memory lapses in a parent...
Target the Core: Why 'Deep Remission' Is the New Gold Standard in Inflammatory Bowel Disease Treatment
Treatment for inflammatory bowel disease is rapidly moving beyond simple symptom management toward the structural...